267 related articles for article (PubMed ID: 34161330)
1. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
[TBL] [Abstract][Full Text] [Related]
2. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer.
Hou MF; Luo CW; Chang TM; Hung WC; Chen TY; Tsai YL; Chai CY; Pan MR
Exp Cell Res; 2017 Oct; 359(2):458-465. PubMed ID: 28842166
[TBL] [Abstract][Full Text] [Related]
3. CHD4 as an important mediator in regulating the malignant behaviors of colorectal cancer.
Chang CL; Huang CR; Chang SJ; Wu CC; Chen HH; Luo CW; Yip HK
Int J Biol Sci; 2021; 17(7):1660-1670. PubMed ID: 33994851
[TBL] [Abstract][Full Text] [Related]
4. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.
Nio K; Yamashita T; Okada H; Kondo M; Hayashi T; Hara Y; Nomura Y; Zeng SS; Yoshida M; Hayashi T; Sunagozaka H; Oishi N; Honda M; Kaneko S
J Hepatol; 2015 Nov; 63(5):1164-72. PubMed ID: 26095183
[TBL] [Abstract][Full Text] [Related]
5. The epigenetic factor CHD4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract][Full Text] [Related]
6. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.
Guillemette S; Serra RW; Peng M; Hayes JA; Konstantinopoulos PA; Green MR; Cantor SB
Genes Dev; 2015 Mar; 29(5):489-94. PubMed ID: 25737278
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
8. The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
Zhang H; Hu L; Cheng M; Wang Q; Hu X; Chen Q
Oncol Rep; 2020 Dec; 44(6):2610-2620. PubMed ID: 33125122
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
[TBL] [Abstract][Full Text] [Related]
10. CHD4 Predicts Aggressiveness in PTC Patients and Promotes Cancer Stemness and EMT in PTC Cells.
Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Alobaisi K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33419089
[TBL] [Abstract][Full Text] [Related]
11. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.
Luo CW; Wu CC; Chang SJ; Chang TM; Chen TY; Chai CY; Chang CL; Hou MF; Pan MR
Exp Cell Res; 2018 Feb; 363(1):65-72. PubMed ID: 29305962
[TBL] [Abstract][Full Text] [Related]
12. MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.
Ren L; Xiao L; Hu J
J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):721-4. PubMed ID: 18231753
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
14. miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer.
Wu J; Zhang L; Wu S; Yi X; Liu Z
Pathol Res Pract; 2020 Jul; 216(7):152979. PubMed ID: 32534701
[TBL] [Abstract][Full Text] [Related]
15. CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis.
Wu J; Zhou Z; Li J; Liu H; Zhang H; Zhang J; Huang W; He Y; Zhu S; Huo M; Liu M; Zhang C
Drug Resist Updat; 2023 Jan; 66():100913. PubMed ID: 36603431
[TBL] [Abstract][Full Text] [Related]
16. Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer.
Yang J; Xing H; Lu D; Wang J; Li B; Tang J; Gu F; Hong L
J Cell Mol Med; 2019 Jun; 23(6):4005-4018. PubMed ID: 30993885
[TBL] [Abstract][Full Text] [Related]
17. FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer.
Lu M; Chen X; Xiao J; Xiang J; Yang L; Chen D
Arch Med Res; 2018 Feb; 49(2):84-88. PubMed ID: 29716743
[TBL] [Abstract][Full Text] [Related]
18. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
19. CHD4 mediates proliferation and migration of non-small cell lung cancer via the RhoA/ROCK pathway by regulating PHF5A.
Xu N; Liu F; Wu S; Ye M; Ge H; Zhang M; Song Y; Tong L; Zhou J; Bai C
BMC Cancer; 2020 Mar; 20(1):262. PubMed ID: 32228507
[TBL] [Abstract][Full Text] [Related]
20. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
